Sugi Predict

Sugi Predict / Compounds / SCHEMBL8268583

SCHEMBL8268583

SCHEMBL8268583

CCCc1cc(Oc2ccc(S(C)(=O)=O)cc2)ccc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ HTT P42858 3/20 0.41
▸ LMNA P02545 3/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ PTGS2 P35354 5/20 0.39
▸ PTGS1 P23219 4/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ MMP14 P50281 1/20 0.39
▸ MAPT P10636 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ BRD4 O60885 1/20 0.38
▸ GCK P35557 1/20 0.38
▸ NR1H2 P55055 1/20 0.38
▸ NR1H3 Q13133 1/20 0.38
▸ FFAR4 Q5NUL3 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5209631 0.84 PPARG (0.43) PPARGSLC6A4HTTLMNASMN1; SMN2
SCHEMBL28382945 0.84 TAAR1 (0.44) PPARGSLC6A4LMNASMN1; SMN2L3MBTL1
SCHEMBL13679030 0.81 TAAR1 (0.47) PPARGSLC6A4HTTLMNASMN1; SMN2
SCHEMBL8259798 0.80 LTA4H (0.49) PPARGNPC1RAB9ATDP1L3MBTL1
SCHEMBL8259799 0.78 PPARG (0.46) PPARGSLC6A4LMNAMAPTATM
SCHEMBL14431706 0.76 SLC6A4 (0.47) SLC6A4HTTLMNANPC1RAB9A
SCHEMBL14431591 0.76 PPARG (0.38) PPARGLMNARAB9AL3MBTL1ALDH1A1
SCHEMBL11547843 0.75 HTT (0.58) HTTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL8262759 0.75 PPARG (0.41) PPARGSLC6A4LMNARAB9AL3MBTL1
SCHEMBL10357434 0.74 TAAR1 (0.37) PPARGSMN1; SMN2PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110251171-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE BACH ANDREW THOMAS 2011-10-13 — — US disclosed
US-20100152255-A1 Organic Compounds DAMON ROBERT EDSON 2010-06-17 — — US disclosed
US-7652061-B2 N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors NOVARTIS A.G. (CH) 2010-01-26 — — US disclosed
US-20080221336-A1 Pparalpha/Gamma Agonists and Processes of Preparing GARRETT CHRISTINE E 2008-09-11 — — US disclosed
US-20080131475-A1 Methods of Use of Dual Ppar Agonist Compounds and Drug Delivery Devices Containing Such Compounds COHEN DAVID SAUL 2008-06-05 — — US disclosed
US-20070299047-A1 Combination of Organic Compounds MAHER WILLIAM 2007-12-27 — — US disclosed
US-20070135502-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE BACH ANDREW T 2007-06-14 — — US disclosed
US-7183304-B2 such as (R)-1-{4-[4-(4-Phenoxy-2-propyl-phenoxy)-butoxy]-benzenesulfonyl}-azetidine-2-carboxylic acid, used as peroxisome proliferator-activated receptor agonists; hypoglycemic agents NOVARTIS AG (CH) 2007-02-27 — — US disclosed
US-20070043020-A1 Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds NOVARTIS AG (CH) 2007-02-22 — — US disclosed
US-20070004704-A1 Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X NOVARTIS AG (CH) 2007-01-04 — — US disclosed
WO-2006029349-A1 COMBINATION OF ORGANIC COMPOUNDS NOVARTIS AG (CH) 2006-03-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152255-A1 Organic Compounds PPARG, FABP2, PPARA PPARG 1/4885SLC6A4 4592/4885HTT 2847/4885
US-20110251171-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PPARG, PPARA, PPARD PPARG 1/4885SLC6A4 4665/4885HTT 2218/4885
US-20070135502-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PPARG, PPARA, PPARD PPARG 1/4885SLC6A4 4665/4885HTT 2218/4885
US-20070043020-A1 Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds PPARG, PPARA, PPARD PPARG 1/4885SLC6A4 4630/4885HTT 3349/4885
US-20070299047-A1 Combination of Organic Compounds GLP1R, PPARG, GCGR PPARG 2/4885SLC6A4 1125/4885HTT 3123/4885
US-20080221336-A1 Pparalpha/Gamma Agonists and Processes of Preparing PPARA, PPARG, PPARD PPARG 2/4885SLC6A4 4277/4885HTT 4418/4885
US-20070004704-A1 Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X PPARG, GPR119, PPARA PPARG 1/4885SLC6A4 4564/4885HTT 3546/4885
US-20080131475-A1 Methods of Use of Dual Ppar Agonist Compounds and Drug Delivery Devices Containing Such Compounds PPARA, PPARD, PPARG PPARG 3/4885SLC6A4 1633/4885HTT 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.